Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR (epithelial growth factor receptor), frequently...
- Mechanism
- Curator reviewed
Matuzumab binds the epidermal growth factor receptor (EGFR) with high affinity, competitively blocking natural ligand binding and blocking receptor-mediated downstream signalling, resulting in impaired tumor cell proliferation. Matuzumab (EMD-72000) is a humanized IgG1 MAb that not only binds with high specificity and affinity to EGFR, but also modulates antibody-dependent cellular cytotoxicity (ADCC).
- Primary indication
- Investigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.Curator reviewed
- Code names
- EMD-72000
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Matuzumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account